Cullinan Therapeutics Inc.
Organization details
- Legal name
- Cullinan Therapeutics Inc.
- Former names
- Cullinan Oncology, Inc. Cullinan Management, Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Cambridge
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- CGEM
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001789972
- EIN
- 81-3879991
Board of directors
-
Andrew R. Allen · DirectorSince 2025
-
Anne-Marie Martin · DirectorSince 2023
-
Anthony Rosenberg · DirectorSince 2023
-
David D. Meek · DirectorSince 2024
-
David P. Ryan · DirectorSince 2024
- Since 2024
-
Mittie Doyle · DirectorSince 2025
-
Nadim Ahmed · Director · President and CEOSince 2023
-
Stephen W. Webster · DirectorSince 2023
-
Thomas Ebeling · DirectorSince 2023
Chief executives
Director election results
Annual meeting of June 16, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
74.5%
-
75.6%
Board connections
4 of this board's directors also sit on 8 other boards. 8 are in the same sector.
-
Aktis Oncology Inc. Same sectorvia Mary Thistle
-
Alaunos Therapeutics Inc. Same sectorvia Mary Thistle
-
Disc Medicine Inc. Same sectorvia Nadim Ahmed
-
Eloxx Pharmaceuticals Inc. Same sectorvia Stephen W. Webster
-
Entrada Therapeutics Inc. Same sectorvia Mary Thistle
-
NextCure Inc. Same sectorvia Stephen W. Webster
-
Q32 Bio Inc. Same sectorvia Mary Thistle
-
uniQure N.V. Same sectorvia David D. Meek
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $2,558,836
- 29 sales by 5 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 5, 2026 | Michaelson Jennifer Officer (Chief Scientific Officer) | Option exercise | +3,805 | $4.30 | $16,362 |
| Nov 5, 2026 | Michaelson Jennifer Officer (Chief Scientific Officer) | Open-market sale | −4,000 | $12.36 | $49,440 |
| Sep 8, 2026 | Michaelson Jennifer Officer (Chief Scientific Officer) | Option exercise | +4,000 | $4.30 | $17,200 |
| Sep 8, 2026 | Michaelson Jennifer Officer (Chief Scientific Officer) | Open-market sale | −8,000 | $21.57 | $172,560 |
| Aug 13, 2026 | Michaelson Jennifer Officer (Chief Scientific Officer) | Option exercise | +30,000 | $4.30 | $129,000 |
| Aug 13, 2026 | Michaelson Jennifer Officer (Chief Scientific Officer) | Open-market sale | −30,000 | $20.26 | $607,800 |
| Jul 6, 2026 | Michaelson Jennifer Officer (Chief Scientific Officer) | Option exercise | +4,000 | $4.30 | $17,200 |
| Jul 6, 2026 | Michaelson Jennifer Officer (Chief Scientific Officer) | Open-market sale | −8,000 | $17.82 | $142,560 |
| Jun 30, 2026 | Fenton Mary Kay Officer (Chief Financial Officer) | Grant or award | +1,541 | $8.60 | $13,253 |
| Jun 30, 2026 | SUMER JACQUELYN L Officer (Chief Legal Officer) | Grant or award | +2,470 | $8.60 | $21,242 |
| May 5, 2026 | Michaelson Jennifer Officer (Chief Scientific Officer) | Option exercise | +4,000 | $4.30 | $17,200 |
| May 5, 2026 | Michaelson Jennifer Officer (Chief Scientific Officer) | Open-market sale | −7,800 | $14.60 | $113,880 |
| May 5, 2026 | Michaelson Jennifer Officer (Chief Scientific Officer) | Open-market sale | −200 | $15.58 | $3,116 |
| Mar 5, 2026 | Michaelson Jennifer Officer (Chief Scientific Officer) | Option exercise | +4,000 | $4.30 | $17,200 |
| Mar 5, 2026 | Michaelson Jennifer Officer (Chief Scientific Officer) | Open-market sale | −8,000 | $15.68 | $125,440 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Cullinan Therapeutics Inc.
Who is the CEO of Cullinan Therapeutics Inc.?
Nadim Ahmed is Cullinan Therapeutics Inc.'s President and CEO.
How many directors are on Cullinan Therapeutics Inc.'s board?
Cullinan Therapeutics Inc.'s board has 10 directors: Andrew R. Allen, Anne-Marie Martin, Anthony Rosenberg, David D. Meek, David P. Ryan, Mary Thistle, Mittie Doyle, Nadim Ahmed, Stephen W. Webster and Thomas Ebeling.
Are Cullinan Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Cullinan Therapeutics Inc. insiders made no open-market purchases and sold $2.6 million of shares in 29 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="cullinan-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.